graft-versus-host disease
BioSenic seeks to survive cash crunch and enter phase 3 for GvHD drug
Anika Sharma
BioSenic, the Belgian biotech born from the merger of Bone Therapeutics and Medsenic last year, is devising a survival plan ...
Mesoblast hopes to win FDA approval for remestemcel-L after meeting with regulators
Anika Sharma
Mesoblast, a biotech company based in Melbourne, Australia, is making determined strides toward securing FDA approval for its off-the-shelf therapy, ...
